iSAM Funds UK Ltd Purchases Shares of 5,438 Revvity, Inc. (NYSE:RVTY)

iSAM Funds UK Ltd acquired a new stake in Revvity, Inc. (NYSE:RVTY - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,438 shares of the company's stock, valued at approximately $607,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tidal Investments LLC raised its stake in shares of Revvity by 82.7% in the fourth quarter. Tidal Investments LLC now owns 96,459 shares of the company's stock valued at $10,766,000 after acquiring an additional 43,672 shares in the last quarter. Toronto Dominion Bank raised its stake in shares of Revvity by 40.7% in the fourth quarter. Toronto Dominion Bank now owns 58,374 shares of the company's stock valued at $6,515,000 after acquiring an additional 16,881 shares in the last quarter. Siemens Fonds Invest GmbH raised its stake in shares of Revvity by 264.8% in the fourth quarter. Siemens Fonds Invest GmbH now owns 13,357 shares of the company's stock valued at $1,491,000 after acquiring an additional 9,696 shares in the last quarter. Royal Bank of Canada raised its stake in shares of Revvity by 4.7% in the fourth quarter. Royal Bank of Canada now owns 304,376 shares of the company's stock valued at $33,971,000 after acquiring an additional 13,641 shares in the last quarter. Finally, Rafferty Asset Management LLC raised its holdings in shares of Revvity by 10.3% in the 4th quarter. Rafferty Asset Management LLC now owns 13,799 shares of the company's stock valued at $1,540,000 after purchasing an additional 1,288 shares in the last quarter. Hedge funds and other institutional investors own 86.65% of the company's stock.

Revvity Stock Performance

NYSE:RVTY traded down $1.01 during mid-day trading on Friday, reaching $89.47. The stock had a trading volume of 1,023,503 shares, compared to its average volume of 951,592. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. The firm has a market capitalization of $10.55 billion, a price-to-earnings ratio of 40.48, a PEG ratio of 3.82 and a beta of 1.02. Revvity, Inc. has a twelve month low of $88.01 and a twelve month high of $129.50. The business has a 50 day simple moving average of $96.71 and a 200 day simple moving average of $109.21.

Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings data on Monday, April 28th. The company reported $1.01 EPS for the quarter, beating analysts' consensus estimates of $0.96 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. The firm had revenue of $664.76 million during the quarter, compared to the consensus estimate of $662.30 million. During the same quarter last year, the firm earned $0.98 earnings per share. The firm's revenue was up 2.3% compared to the same quarter last year. On average, analysts expect that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Investors of record on Friday, July 18th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date of this dividend is Friday, July 18th. Revvity's payout ratio is currently 11.91%.

Analyst Ratings Changes

Several equities analysts recently commented on RVTY shares. The Goldman Sachs Group dropped their target price on Revvity from $140.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. KeyCorp raised their price objective on Revvity from $132.00 to $145.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Raymond James reaffirmed an "outperform" rating and set a $120.00 price objective (down previously from $145.00) on shares of Revvity in a report on Tuesday, April 29th. UBS Group raised Revvity from a "neutral" rating to a "buy" rating and dropped their price objective for the stock from $145.00 to $115.00 in a report on Thursday, May 1st. Finally, Barclays dropped their price objective on Revvity from $140.00 to $110.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Five analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $125.64.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.